Mark Crawford is a founding partner of Skikos, Crawford, Skikos & Joseph, and has more than 25 years’ experience in complex litigation, including pharmaceutical drug and medical device cases.
Mark is currently the court-appointed Plaintiffs’ Co-Liaison Counsel for the California Risperdal JCCP coordinated proceedings in Los Angeles, and Plaintiffs’ Co-Lead Counsel for the California Fosamax coordinated proceedings in Orange County. He is also on the Plaintiffs’ Complaint and Law and Briefing committees for the federal opioid MDL proceedings.
Mark does extensive appellate work and Supreme Court briefing in the pharmaceutical field, and is a member of the United States Supreme Court Bar. Mark’s appellate work includes briefing and arguing Teva Pharmaceuticals v. Superior Court (2013) 217 Cal.App.4th 96, cert. denied, 2015 U.S. LEXIS 687 (U.S., Jan. 20, 2015), which found state law failure to warn claims against generic drug manufacturers are not preempted under federal law.